Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

 

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
C

Should MRD Positivity Guide Therapy in Non-M3 AML? MRD Positivity Is Not Currently Supported by Clinical Evidence

By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Chetasi Talati
By Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies FEATURING Chetasi Talati
13 views
January 27, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
AML
17:31
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Navigating the Landscape of Best Frontline Therapies for AML in Olde…

Feat. K. Sweet
20:28
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

42 y/o Female With FLT3 + AML: What Should Initial Therapy Be and Is…

Feat. A. Perl
16:01
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Should MRD Positivity Guide Therapy in Non-M3 AML? MRD Is Strongly C…

Feat. D. Sallman
23:42
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Should MRD Positivity Guide Therapy in Non-M3 AML? MRD Positivity Is…

Feat. C. Talati